16
Jan
2025

J&J Doubles Down on Neuro, Lilly Acquires Scorpion, Umoja Pulls in $100M

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Gilead Acquires Arcellx, Alkermes Passes the Torch, Beam Borrows Big
FDA Flip-Flops on Flu Vaccine, Compass Passes Phase 3, & J&J Bets on Pennsylvania
Eikon Goes Public, Generate Biomedicines Teed Up, & Sante Reloads
Eikon IPO on Deck, Biomarin Borrows Big, & Halozyme Rolls with the Surf